Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma

Figure 3 Overall hepatocellular carcinoma patient survival based on serum levels of manganese superoxide dismutase or thioredoxin. Overall survival was plotted using the Kaplan-Meier method after separation into two or three groups defined as follows: A: Manganese superoxide dismutase (MnSOD) < 110 ng/mL or ≥ 110 ng/mL; B: Thioredoxin (TRX) < 80 ng/mL or ≥ 80 ng/mL; TRX ≥ 80 ng/mL, TRX < 80 ng/mL; C: MnSOD < 110 ng/mL, or TRX < 80 ng/mL and MnSOD ≥ 110 ng/mL. The overall survival rate was lower in patients with MnSOD levels ≥ 110 ng/mL (P = 0.01) (A). Also, cumulative patient survival rate tended to be lower in patients with TRX levels < 80 ng/mL (P = 0.05) (B). Among these groups, patients with serum TRX levels < 80 ng/mL and serum MnSOD levels ≥ 110 ng/mL had the poorest prognosis (C).